All In Biotech

Drug Trial Radar · NCT00930553

An Extension Protocol for Multiple Sclerosis Patients Who Participated in Genzyme-Sponsored Studies of Alemtuzumab

Last checked: Nov 20, 2026Latest source record: May 15, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,314

Actual

Start

Aug 2009

Primary completion

Feb 2016

Study completion Feb 2016

Sponsor

Lead sponsor
Genzyme, a Sanofi CompanySanofi (SNY)
Sponsor type
Industry
Collaborators
Bayer
First posted
Jun 30, 2009

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Non randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This open-label, rater-blinded extension study enrolled participants who had relapsing-remitting multiple sclerosis (RRMS) and who participated in one of three prior Genzyme-sponsored studies of alemtuzumab (CAMMS223 \[NCT00050778\], CAMMS323 \[NCT00530348\] also known as CARE-MS I, or CAMMS324 \[NCT00548405\] also known as CARE-MS II). The purposes of this study were: 1. To examine the long term safety and efficacy of alemtuzumab treatment in participants who received alemtuzumab as their study treatment in one of the prior studies. 2. To examine the safety and efficacy of initial alemtuzumab treatment in this study for participants who received Rebif® (interferon beta-1a) as their study treatment in one of the prior studies. 3. To determine the safety and efficacy of additional "as needed" alemtuzumab treatment courses. This applied both to participants who received alemtuzumab for the first time in one of the prior studies or for the first time in this extension study.

Conditions

  • Multiple Sclerosis, Relapsing-Remitting

Interventions

  • alemtuzumabBiological

    Alemtuzumab 12 mg/day IV infusion on 5 consecutive days if the participants had no prior alemtuzumab exposure (ie, first treatment course). All subsequent treatment courses were for 3 days only.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Annualized Relapse Rate (ARR)Time frame: Year 3, 4, 5, 6 from the Baseline (Month 0 of CAMMS323 and Month 0 of CAMMS324 for "Alemtuzumab Treatment CAMMS323 Extension" group and "Alemtuzumab Treatment CAMMS324 Extension" group, respectively)
  2. Annualized Relapse Rate (ARR) Before and After Receiving AlemtuzumabTime frame: Baseline (Year 0 of initial studies) up to Year 4
  3. Annualized Relapse Rate (ARR) Before and After Alemtuzumab RetreatmentTime frame: Year 1 prior to retreatment, Year 1, 2, 3 after retreatment
  4. Number of Participants With Sustained Accumulation of Disability (SAD)Time frame: Baseline (Year 0) up to Year 6
  5. Number of Participants With Sustained Accumulation of Disability (SAD) Before and After Alemtuzumab Treatment: 2 Year ComparisonTime frame: Baseline (Year 0 of initial studies) up to Year 4

Locations

176 sites in 23 countries. Site status is shown where the registry gives one.

  • North Central Neurology Associates, P.C.

    Cullman, Alabama

  • HOPE Research Institute

    Phoenix, Arizona

  • St. Joseph's Hospital and Medical Center Barrow Neurology Clinics - Barrow Neurological Institute

    Phoenix, Arizona

  • Mayo Clinic Arizona (Scottsdale)

    Scottsdale, Arizona

  • Northwest NeuroSpecialists, PLLC

    Tucson, Arizona

  • East Bay Physicians Medical Group/ Sutter East Bay Medical Foundation

    Berkeley, California

  • Neurology Center North Orange County

    La Habra, California

  • University of Southern California Keck School of Medicine/University of Southern California LAC & USC Medical Center

    Los Angeles, California

  • Neuro-Therapeutics, Inc.

    Pasadena, California

  • Stanford University Medical Center

    Stanford, California

  • University of Colorado Health Science Center - Aurora

    Aurora, Colorado

  • Advanced Neurology of Colorado

    Fort Collins, Colorado

  • Yale MS Research Center

    New Haven, Connecticut

  • The George Washington University Medical Faculty Associates

    Washington D.C., District of Columbia

  • University of Florida Neuroscience Institute

    Jacksonville, Florida

  • Neurology Associates, P.A.

    Maitland, Florida

  • Neurological Associates

    Pompano Beach, Florida

  • Negroski, Stein, Sutherland and Hanes Neurology

    Sarasota, Florida

  • Axiom Clinical Research of Florida

    Tampa, Florida

  • University of South Florida College of Medicine

    Tampa, Florida

  • Emory University Department of Neurology

    Atlanta, Georgia

  • Shepherd Center Multiple Sclerosis Institute

    Atlanta, Georgia

  • University of Chicago Medical Center

    Chicago, Illinois

  • Consultants in Neurology, LTD

    Northbrook, Illinois

  • Fort Wayne Neurological Center

    Fort Wayne, Indiana

  • Indiana University Multiple Sclerosis Center

    Indianapolis, Indiana

  • Iowa Health Physicians

    Des Moines, Iowa

  • Ruan Neurology Clinic and Clinical Research Center, Mercy Medical Center

    Des Moines, Iowa

  • University of Kansas Medical Center, Department of Neurology

    Kansas City, Kansas

  • MidAmerica Neuroscience Institute

    Lenexa, Kansas

  • Associates in Neurology, P.S.C.

    Lexington, Kentucky

  • Kentucky Neuroscience Research

    Louisville, Kentucky

  • University of Maryland, Maryland Center for MS

    Baltimore, Maryland

  • The MS Center at St. Elizabeth's

    Boston, Massachusetts

  • UMass Memorial Medical Center

    Worcester, Massachusetts

  • University of Michigan Medical School

    Ann Arbor, Michigan

  • Michigan Neurology Association

    Clinton, Michigan

  • Wayne State University, The School of Medicine, Department of Neurology

    Detroit, Michigan

  • Spectrum Health Medical Group, Neurology/Michigan Medical P.C., West Michigan MS Clinic

    Grand Rapids, Michigan

  • Northern Michigan Neurology

    Traverse City, Michigan

Showing 40 of 176 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.